Search clinical trials for: Docetaxel or Paclitaxel

Total 11413 results

pharmaand GmbH
Foundation Medicine

Active, not recruiting

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Metastatic Castration Resistant Prostate Cancer

United States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
University of Michigan Rogel Cancer Center

Completed

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Prostate Cancer

United States
Peregrine Pharmaceuticals

Completed

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Non-small-cell Lung Cancer

United States, India, Georgia, Russian Federation, Ukraine
US Oncology Research
Genentech, Inc.

Terminated

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Breast Neoplasms | Malignant Tumor of the Breast

United States
Lawson Health Research Institute
The Ottawa Hospital

Completed

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Breast Neoplasms

Canada
Dr. Gordon Buduhan
University of Toronto; London Health Sciences Centre; CancerCare Manitoba

Recruiting

Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (POWERRANGER)

Esophageal Cancer | Adenocarcinoma, Esophageal | Adenocarcinoma, Gastroesophageal Junction

Canada
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States
University of Illinois at Chicago

Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer (BRE-10)

Breast Cancer | HER2-positive Breast Cancer

United States
National University Hospital, Singapore
The N.1 Institute for Health (N.1); Cancer Science Institute of Singapore

Not yet recruiting

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

Singapore
AstraZeneca

Completed

Iressa 2nd Line Phase III Study in Japan

Non-Small Cell Lung Cancer

Japan
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer

Breast Cancer,Her2 Positive

China
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (STORM)

Metastatic Breast Cancer | Recurrent Breast Cancer

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (SAPPHIRE)

Breast Cancer

Australia
Tao Zhang

Recruiting

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

Gastric Cancer Stage IV

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Breast Cancer

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
Xencor, Inc.

Recruiting

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Guangdong Provincial People's Hospital

Unknown

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Breast Cancer

China
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)

Breast Neoplasms

Italy, Netherlands, Belgium, United Kingdom, Argentina, Austria, Brazil, China, Ecuador, Estonia, Finland, France, Germany, Greece, Mexico, Peru, Poland, Portugal, Slovenia, Spain, United Arab Emirates, Canada, Hungary, Israel, Sweden, Tu... and more
Samsung Medical Center

Unknown

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Non-small Cell Lung Cancer Metastatic

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Breast Cancer

China
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain
Jinghui Wang

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Cancer

China
GlaxoSmithKline

Completed

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Neoplasms

United States, Denmark, Spain, Belgium, United Kingdom, Russian Federation, Netherlands
NYU Langone Health

Completed

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Breast Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Stage IV Esophagus Squamous Cell Carcinoma

China
Universitaire Ziekenhuizen KU Leuven
AstraZeneca

Active, not recruiting

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer (CLIO)

Ovarian Epithelial Cancer

Belgium
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Breast Cancer

China
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Endometrial Neoplasms

Australia, United States, Germany, Israel, Korea, Republic of, Poland, Turkey, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, Hungary, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Russian Federation, Spain, Swed... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Esophageal Carcinoma | Esophagogastric Junction Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
SOTIO a.s.

Terminated

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Epithelial Ovarian Carcinoma

Germany, Poland, Czech Republic
University of Texas Southwestern Medical Center

Active, not recruiting

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (DARTBOARD)

Head and Neck Cancer

United States
Amgen

Completed

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Melanoma

China
Fudan University
Chinese Anti-Cancer Association

Completed

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Primary Breast Cancer

China
First People's Hospital of Hangzhou

Recruiting

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Relapsed Small Cell Lung Cancer | Anlotinib

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
Sun Yat-sen University

Unknown

Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer (SYSGO-003)

Quality of Life | PFS | OS

China
Erasme University Hospital
Jules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...

Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic Neoplasm

Belgium
Peking Union Medical College Hospital

Recruiting

DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease

Safety Issues | Efficacy, Self

China

3

Subscribe